Fountain Therapeutics, Inc.

South San Francisco, CA · Founded 2018 · Biotech · Private

Small molecule therapeutics for skin and skeletal muscle atrophy identified through proprietary screening platforms

Claim this profile

Follows are private to you and power your alerts

Updated · fountainml.com

Sector
Biotech
Headquarters
South San Francisco, CA
Founded
2018
Latest Form D
$15.9M, Dec 2021
Total capital
$26.9M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$26.9M
3 Form D · last Dec 2021
59 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
8 pending

Capital timeline

2018201920202021FEDERAL ↑EQUITY ↓Cumulative $26.9M1st Form D$5M2nd Form D$6M3rd Form D$15.9M
2018201920202021FEDERAL ↑EQUITY ↓Cumulative $26.9M2nd Form D$6M3rd Form D$15.9M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$15.9M
  • Private capital raisedForm D · SEC · 2nd filing$6M
  • Private capital raisedForm D · SEC · 1st filing$5M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Alex MorganDirectorNamed in SEC Form D filings
  • Ashish KhannaDirectorNamed in SEC Form D filings
  • John DimosExecutive Officer, DirectorNamed in SEC Form D filings
  • Thomas RandoExecutive Officer, DirectorNamed in SEC Form D filings
  • William GreeneExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 8
  • PendingUse Of Selective VEGFR2 And FGFR1 InhibitorsUSPTOApplication 18332357
  • PendingMethods & Compositions For Treating Dermal AtrophyUSPTOApplication 63665766
  • PendingMethods & Compositions For Treating Dermal AtrophyUSPTOApplication 63637931
Show all 8 patent records
  • Use Of Selective VEGFR2 And FGFR1 InhibitorsMay 16, 2024 · Application 18332357Pending
  • Methods & Compositions For Treating Dermal AtrophyApplication 63665766Pending
  • Methods & Compositions For Treating Dermal AtrophyApplication 63637931Pending
  • Methods & Compositions For Treating Dermal AtrophyApplication 63636193Pending
  • Methods & Compositions For Treating Dermal AtrophyApplication 63564750Pending
  • Use Of Selective VEGFR2 And FGFR1 InhibitorsApplication PCTUS2023068247Pending
  • Methods & Compositions For Treating Dermal AtrophyApplication PCTUS2025019792Pending
  • Use Of Selective VEGFR2 And FGFR1 InhibitorsApplication 63351254Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .